Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy.

Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy.

<h4>Background</h4>Studies have indicated that programmed death ligand 1 (PD-L1) expression may have utility as a predictive biomarker in patients with advanced/metastatic urothelial carcinoma (UC). Different immunohistochemical (IHC) assays are in development to assess PD-L1 expression...

Full description

Bibliographic Details
Main Authors:	Magdalena Zajac, Jiabu Ye, Pralay Mukhopadhyay, Xiaoping Jin, Yong Ben, Joyce Antal, Ashok K Gupta, Marlon C Rebelatto, J Andrew Williams, Jill Walker
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2020-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0231936

Similar Items

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
by: Faiena I, et al.
Published: (2018-01-01)

Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
by: Baldini C, et al.
Published: (2019-04-01)

279 Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival
by: Lukas Kaesmann, et al.
Published: (2020-11-01)

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract
by: Michal Sarfaty, et al.
Published: (2021-02-01)

Interpretation According to Clone-Specific PD-L1 Cutoffs Reveals Better Concordance in Muscle-Invasive Urothelial Carcinoma
by: Tzu-Hao Huang, et al.
Published: (2021-03-01)

Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma
by: Magdalena Zajac, et al.
Published: (2019-09-01)

Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer
by: Eun Young Kim, et al.
Published: (2019-04-01)

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
by: Shuguang Tan, et al.
Published: (2017-05-01)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
by: Hyun Tae Lee, et al.
Published: (2017-07-01)

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy
by: Meilin Jiang, et al.
Published: (2020-06-01)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
by: Siddharth Sheth, et al.
Published: (2020-07-01)

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting
by: Julian Taugner, et al.
Published: (2021-03-01)

Retinal Vasculitis Secondary to Durvalumab
by: Antonio R. Andrade, et al.
Published: (2020-05-01)

Germline Variation in <i>PDCD1</i> Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
by: Mirjam de With, et al.
Published: (2021-03-01)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
by: Tadaaki Yamada, et al.
Published: (2020-05-01)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
by: Bin Zhao, et al.
Published: (2020-07-01)

Skin puckering and edema during durvalumab therapy
by: Brianna Olamiju, BA, et al.
Published: (2021-01-01)

Durvalumab in NSCLC: latest evidence and clinical potential
by: Nerea Muñoz-Unceta, et al.
Published: (2018-10-01)

Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
by: Shivani Patel, et al.
Published: (2019-12-01)

Phimosis: A rare complication of immunotherapy with durvalumab
by: Luis Gabriel Vázquez-Lavista, et al.
Published: (2020-11-01)

Durvalumab induced sarcoid‐like pulmonary lymphadenopathy
by: Emma Sanderson, et al.
Published: (2020-04-01)

78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma
by: Yun Zhang, et al.
Published: (2020-11-01)

PD-L1 blockade for urothelial carcinoma
by: Josephine Kang, et al.
Published: (2017-07-01)

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-10-01)

Progress in the treatment of Bladder Urothelial Carcinoma with PD-1 / PD-L inhibitor
by: Tao Zhang, et al.
Published: (2019-04-01)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
by: Xia Xiao, et al.
Published: (2021-01-01)

PK-PD Integration Modeling and Cutoff Value of Florfenicol against Streptococcus suis in Pigs
by: Zhixin Lei, et al.
Published: (2018-01-01)

Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma
by: Jack Patrick Gleeson, et al.
Published: (2020-01-01)

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
by: Yu-Feng Zhou, et al.
Published: (2020-03-01)

Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use
by: Sean C. Dougherty, et al.
Published: (2021-06-01)

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
by: Mary H. Young, et al.
Published: (2021-08-01)

Durvalumab-Induced Diffuse Alveolar Hemorrhage: An Autopsy Case Report
by: Kensuke Kanaoka, et al.
Published: (2020-06-01)

Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
by: Yang H, et al.
Published: (2018-07-01)

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
by: Erwin H.J. Tonk, et al.
Published: (2019-08-01)

363 Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result
by: Byoung Chul Cho, et al.
Published: (2020-11-01)

Optimal regimens based on PK/PD cutoff evaluation of ceftiofur against Actinobacillus pleuropneumoniae in swine
by: Da Sun, et al.
Published: (2020-09-01)

Effects of monotherapy versus combination therapy on overall and disease-free survival in high-grade astrocytoma
by: Amouzegar Hashemi F., et al.
Published: (2007-09-01)

Determining the optimal cutoff point for lymph node density and its impact on overall survival in children with Wilms’ tumor
by: Pan Z, et al.
Published: (2019-01-01)

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
by: Antoine Hollebecque, et al.
Published: (2021-03-01)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
by: Yihang Qi, et al.
Published: (2021-06-01)